pH and redox triggered doxorubicin release from covalently linked carbon dots conjugates

Research on Red/Near-Infrared Fluorescent Carbon Dots Based on Different Carbon Sources and Solvents: Fluorescence Mechanism and Biological Applications

Fluorescent carbon dots, especially red/near-infrared-emitting CDs, are becoming increasingly important in the field of biomedicine. This article reviews the synthesis, fluorescence mechanisms, and biological applications of R/NIR-CDs, emphasizing the importance of carbon source and solvent selection in controlling their optical properties. The formation process of CDs is classified, and the fluorescence mechanisms of CDs are summarized, involving carbon core states, surface states, molecular states, and cross-linking enhanced emission effects. This article also highlights the applications of R/NIR-CDs in bioimaging, biosensing, phototherapy, and drug delivery. The final section discusses challenges and prospects.

FericipXT-coated PEGylated rutile TiO2 nanoparticles in drug delivery: in vitro assessment of imatinib release

This study presents a facile synthesis strategy for magnetic field-responsive PEGylated iron-supplement-coated rutile titanium dioxide (TiO2) nanoparticles (NPs) for stimulus-responsive drug delivery. Imatinib, an anticancer drug, was successfully loaded into NPs, and its in vitro release was investigated under different pH conditions. XRD analysis confirmed the successful synthesis of PEGylated iron supplement-coated rutile titania NPs. HR-TEM studies revealed an increased NP size due to the coating, PEGylation, and drug loading, which was corroborated by FTIR spectra, confirming the drug loading into the NPs. DLS provided a hydrodynamic diameter of 642.2 nm and polydispersity index of 0.277 for PEGylated NPs, indicating their enhanced biodistribution and narrow size distribution. PEGylated NPs exhibited a negative zeta potential of -32.89 mV, indicating high stability. In vitro drug-release studies demonstrated controlled release with maximum efficiency under acidic conditions. Hemolysis assay confirmed the safety and biocompatibility of PEGylated NPs. All drug-loaded nanoformulations followed the Peppas-Sahlin model, suggesting Fickian diffusion and Case II relaxation mechanism of drug release. These NPs have the potential for the targeted delivery and controlled release of chemotherapeutics, thereby minimizing side effects.

Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement

Antibody-drug conjugates (ADCs) represent a novel and promising approach in targeted therapy, uniting the specificity of antibodies that recognize specific antigens with payloads, all connected by the stable linker. These conjugates combine the best targeted and cytotoxic therapies, offering the killing effect of precisely targeting specific antigens and the potent cell-killing power of small molecule drugs. The targeted approach minimizes the off-target toxicities associated with the payloads and broadens the therapeutic window, enhancing the efficacy and safety profile of cancer treatments. Within precision oncology, ADCs have garnered significant attention as a cutting-edge research area and have been approved to treat a range of malignant tumors. Correspondingly, the issue of resistance to ADCs has gradually come to the fore. Any dysfunction in the steps leading to the ADCs' action within tumor cells can lead to the development of resistance. A deeper understanding of resistance mechanisms may be crucial for developing novel ADCs and exploring combination therapy strategies, which could further enhance the clinical efficacy of ADCs in cancer treatment. This review outlines the brief historical development and mechanism of ADCs and discusses the impact of their key components on the activity of ADCs. Furthermore, it provides a detailed account of the application of ADCs with various target antigens in cancer therapy, the categorization of potential resistance mechanisms, and the current state of combination therapies. Looking forward, breakthroughs in overcoming technical barriers, selecting differentiated target antigens, and enhancing resistance management and combination therapy strategies will broaden the therapeutic indications for ADCs. These progresses are anticipated to advance cancer treatment and yield benefits for patients.

Co-delivery of carboplatin and doxorubicin using ZIF-8 coated chitosan-poly(N-isopropyl acrylamide) nanoparticles through a dual pH/thermo responsive strategy to breast cancer cells

A dual pH/temperature sensitive core-shell nanoformulation has been developed based on ZIF-8 coated with chitosan-poly(N-isopropyl acrylamide) (CS-PNIPAAm) for co-delivery of doxorubicin (DOX) and carboplatin (CBP) in breast cancer cells. The resulting nanoparticles (NPs) had particle sizes around 200 nm and a zeta potential of about +30 mV. The CBP and DOX loading contents in the final NPs were 11.6 % and 55.54 %, respectively. NPs showed a pH and thermoresponsive drug release profile with a sustained prolonged release under physiological conditions. The in vitro cytotoxicity experiments showed a significant synergism of CBP and DOX to induce the IC50 of 1.96 μg/mL in MCF-7 cells and 4.54 μg/mL in MDA-MB-231 cells. Also, the final NPs were safer than free DOX and CBP on normal cells. The in vitro study confirmed the higher potency of the designed NPs in combination therapy against breast cancer cells with lower side effects than free drugs.

CARBON DOTS: Bioimaging and Anticancer Drug Delivery

Cancer, responsible for approximately 10 million lives annually, urgently requires innovative treatments, as well as solutions to mitigate the limitations of traditional chemotherapy, such as long-term adverse side effects and multidrug resistance. This review focuses on Carbon Dots (CDs), an emergent class of nanoparticles (NPs) with remarkable physicochemical and biological properties, and their burgeoning applications in bioimaging and as nanocarriers in drug delivery systems for cancer treatment. The review initiates with an overview of NPs as nanocarriers, followed by an in-depth look into the biological barriers that could affect their distribution, from barriers to administration, to intracellular trafficking. It further explores CDs' synthesis, including both bottom-up and top-down approaches, and their notable biocompatibility, supported by a selection of in vitro, in vivo, and ex vivo studies. Special attention is given to CDs' role in bioimaging, highlighting their optical properties. The discussion extends to their emerging significance as drug carriers, particularly in the delivery of doxorubicin and other anticancer agents, underscoring recent advancements and challenges in this field. Finally, we showcase examples of other promising bioapplications of CDs, emergent owing to the NPs flexible design. As research on CDs evolves, we envisage key challenges, as well as the potential of CD-based systems in bioimaging and cancer therapy.

An overview on animal/human biomass-derived carbon dots for optical sensing and bioimaging applications

Over the past decade, carbon dots (CDs) have emerged as some of the extremely popular carbon nanostructures for diverse applications. The advantages of sustainable CDs, characterized by their exceptional photoluminescence (PL), high water solubility/dispersibility, non-toxicity, and biocompatibility, substantiate their potential for a wide range of applications in sensing and biology. Moreover, nature offers plant- and animal-derived precursors for the sustainable synthesis of CDs and their doped variants. These sources are not only readily accessible, inexpensive, and renewable but are also environmentally benign green biomass. This review article presents in detail the production of sustainable CDs from various animal and human biomass through bottom-up synthetic methods, including hydrothermal, microwave, microwave-hydrothermal, and pyrolysis methods. The resulting CDs exhibit a uniform size distribution, possibility of heteroatom doping, surface passivation, and remarkable excitation wavelength-dependent/independent emission and up-conversion PL characteristics. Consequently, these CDs have been successfully utilized in multiple applications, such as bioimaging and the detection of various analytes, including heavy metal ions. Finally, a comprehensive assessment is presented, highlighting the prospects and challenges associated with animal/human biomass-derived CDs for multifaceted applications.

Reduction-Responsive Chitosan-Based Injectable Hydrogels for Enhanced Anticancer Therapy

Selective delivery of anticancer drug molecules to the tumor site enhances local drug dosages, which leads to the death of cancer cells while simultaneously minimizing the negative effects of chemotherapy on other tissues, thereby improving the patient's quality of life. To address this need, we developed reduction-responsive chitosan-based injectable hydrogels via the inverse electron demand Diels-Alder reaction between tetrazine groups of disulfide-based cross-linkers and norbornene groups of chitosan derivatives, which were applied to the controlled delivery of doxorubicin (DOX). The swelling ratio, gelation time (90-500 s), mechanical strength (G'~350-850 Pa), network morphology, and drug-loading efficiency (≥92%) of developed hydrogels were investigated. The in vitro release studies of the DOX-loaded hydrogels were performed at pH 7.4 and 5.0 with and without DTT (10 mM). The biocompatibility of pure hydrogel and the in vitro anticancer activity of DOX-loaded hydrogels were demonstrated via MTT assay on HEK-293 and HT-29 cancer cell lines, respectively.

Multifunctional magnetoliposomes as drug delivery vehicles for the potential treatment of Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. Therefore, development of novel technologies and strategies to treat PD is a global health priority. Current treatments include administration of Levodopa, monoamine oxidase inhibitors, catechol-O-methyltransferase inhibitors, and anticholinergic drugs. However, the effective release of these molecules, due to the limited bioavailability, is a major challenge for the treatment of PD. As a strategy to solve this challenge, in this study we developed a novel multifunctional magnetic and redox-stimuli responsive drug delivery system, based on the magnetite nanoparticles functionalized with the high-performance translocating protein OmpA and encapsulated into soy lecithin liposomes. The obtained multifunctional magnetoliposomes (MLPs) were tested in neuroblastoma, glioblastoma, primary human and rat astrocytes, blood brain barrier rat endothelial cells, primary mouse microvascular endothelial cells, and in a PD-induced cellular model. MLPs demonstrated excellent performance in biocompatibility assays, including hemocompatibility (hemolysis percentages below 1%), platelet aggregation, cytocompatibility (cell viability above 80% in all tested cell lines), mitochondrial membrane potential (non-observed alterations) and intracellular ROS production (negligible impact compared to controls). Additionally, the nanovehicles showed acceptable cell internalization (covered area close to 100% at 30 min and 4 h) and endosomal escape abilities (significant decrease in lysosomal colocalization after 4 h of exposure). Moreover, molecular dynamics simulations were employed to better understand the underlying translocating mechanism of the OmpA protein, showing key findings regarding specific interactions with phospholipids. Overall, the versatility and the notable in vitro performance of this novel nanovehicle make it a suitable and promising drug delivery technology for the potential treatment of PD.

An Overview on Carbon Quantum Dots Optical and Chemical Features

Carbon quantum dots are the materials of a new era with astonishing properties such as high photoluminescence, chemical tuneability and high biocompatibility. Since their discovery, carbon quantum dots have been described as nanometric high-fluorescent carbon nanoparticles, but this definition has become weaker year after year. Nowadays, the classification and the physical explanation of carbon quantum dots optical properties and their chemical structure remain matter of debate. In this review, we provide a clear discussion on these points, providing a starting point for the rationalization of their classification and a comprehensive view on the optical and chemical features of carbon quantum dots.

Chalcones as Anti-Glioblastoma Stem Cell Agent Alone or as Nanoparticle Formulation Using Carbon Dots as Nanocarrier

The current prognosis for glioblastoma is dismal. Treatment-resistant glioblastoma stem cells (GSCs) and the failure of most drugs to reach therapeutic levels within the tumor remain formidable obstacles to successful treatment. Chalcones are aromatic ketones demonstrated to reduce malignant properties in cancers including glioblastoma. Nanomedicines can increase drug accumulation and tumor cell death. Carbon-dots are promising nanocarriers that can be easily functionalized with tumor-targeting ligands and anti-cancer drugs. Therefore, we synthesized a series of 4′-amino chalcones with the rationale that the amino group would serve as a “handle” to facilitate covalent attachment to carbon-dots and tested their cytotoxicity toward GSCs. We generated 31 chalcones (22 4′-amino and 9 4′ derivatives) including 5 novel chalcones, and found that 13 had an IC₅₀ below 10 µM in all GSC lines. After confirming that the 4-amino group was not part of the active pharmacophore, chalcones were attached to transferrin-conjugated carbon-dots. These conjugates were significantly more cytotoxic than the free chalcones, with the C-dot-transferrin-2,5, dimethoxy chalcone conjugate inducing up to 100-fold more GSC death. Several of the tested chalcones represent promising lead compounds for the development of novel anti-GSC drugs. Furthermore, designing amino chalcones for carbon-dot mediated drug delivery is a rational and effective methodology.

Two-photon excitable membrane targeting polyphenolic carbon dots for long-term imaging and pH-responsive chemotherapeutic drug delivery for synergistic tumor therapy

Long-term dynamic tracking of cells with theranostics properties remains challenging due to difficulty in preparing and delivering drugs by the probes. Herein, we developed a highly fluorescent one- and two-photon...

Drug Loading of Anthracycline Antibiotics on Carbon Dots Using Circular Dichroism Spectrometry

Drug delivery systems using nanoparticles are currently in the panorama of nanomedicine studies. In oncology, chemotherapeutic regimens using anthracycline antibiotics rely on the dosage of treatments to minimize the severity of side effects on the patient. Therefore, even in targeted delivery systems it is of great importance to quantify the level of drug administrated for dosage and quality control of the treatment. Herein, as a feasible pathway to shed light on improving nano drug quantification procedures, we proposed a simple analytical protocol to quantify the anthracyclines loaded on our nonchiral carbon nitride dots (CNDs) with circular dichroism spectrometry (CD). The calibration curves from the linear relation between ellipticity and concentration of the anthracycline drugs followed by measurements on the CNDs conjugates were used in achieving the quantification technique which showed different drug loading for each anthracycline used such as daunorubicin, doxorubicin, and epirubicin.

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

BACKGROUND

Biomimetic nanotechnology-based RNA interference (RNAi) has been successful in improving theranostic efficacy in malignant tumors. Its integration with hybrid biomimetic membranes made of natural cell membranes fused with liposomal membranes is mutually beneficial and extends their biofunctions. However, limited research has focused on engineering such biomimetics to endow them with unique properties and functions, in particular, those essential for a "smart" drug delivery system, such as a tumor microenvironment (TME)-activated multifunctional biomimetic nanoplatform.

RESULTS

Herein, we utilized an integrated hybrid nanovesicle composed of cancer cell membranes (Cm) and matrix metallopeptidase 9 (MMP-9)-switchable peptide-based charge-reversal liposome membranes (Lipm) to coat lipoic acid-modified polypeptides (LC) co-loaded with phosphoglycerate mutase 1 (PGAM1) siRNA (siPGAM1) and DTX. The nanovesicle presented a negatively charged coating (citraconic anhydride-grafted poly-L-lysine, PC) in the middle layer for pH-triggered charge conversion functionalization. The established chemotherapeutic drug (DTX) co-delivery system CLip-PC@CO-LC nanoparticles (NPs) have a particle size of ~ 193 nm and present the same surface proteins as the Cm. Confocal microscopy and flow cytometry results indicated a greater uptake of MMP-9-treated CLip-PC@CO-LC NPs compared with that of the CLip-PC@CO-LC NPs without MMP-9 pretreatment. The exposure to MMP-9 activated positively charged cell-penetrating peptides on the surface of the hybrid nanovesicles. Moreover, pH triggered membrane disruption, and redox triggered DTX and siRNA release, leading to highly potent target-gene silencing in glycolysis and chemotherapy with enhanced antiproliferation ability. The biodistribution results demonstrated that the CLip-PC@LC-DiR NPs accumulated in the tumor owing to a combination of long blood retention time, homologous targeting ability, and TME-activated characteristics. The CLip-PC@CO-LC NPs led to more effective tumor growth inhibition than the DTX and free siPGAM1 formulations.

CONCLUSIONS

TME-activated cancer cell membrane-liposome integrated hybrid NPs provide an encouraging nanoplatform that combines RNAi with chemotherapy for precise treatment of non-small cell lung cancer.

Near-infrared emitting dual-stimuli-responsive carbon dots from endogenous bile pigments

Carbon dots are biocompatible nanoparticles suitable for a variety of biomedical applications. Careful selection of carbon dot precursors and surface modification techniques has allowed for the development of carbon dots with strong near-infrared fluorescence emission. However, carbon dots that provide strong fluorescence contrast would prove even more useful if they were also responsive to stimuli. In this work, endogenous bile pigments bilirubin (BR) and biliverdin (BV) were used for the first time to synthesize stimuli-responsive carbon dots (BR-CDots and BV-CDots respectively). The precursor choice lends these carbon dots spectroscopic characteristics that are enzyme-responsive and pH-responsive without the need for surface modifications post-synthesis. Both BV- and BR-CDots are water-dispersible and provide fluorescence contrast, while retaining the stimuli-responsive behaviors intrinsic to their precursors. Nanoparticle Tracking Analysis revealed that the hydrodynamic size of the BR-CDots and BV-CDots decreased with exposure to bilirubin oxidase and biliverdin reductase, respectively, indicating potential enzyme-responsive degradation of the carbon dots. Fluorescence spectroscopic data demonstrate that both BR-CDots and BV-CDots exhibit changes in their fluorescence spectra in response to changes in pH, indicating that these carbon dots have potential applications in pH sensing. In addition, BR-CDots are biocompatible and provide near-infrared fluorescence emission when excited with light at wavelengths of 600 nm or higher. This work demonstrates the use of rationally selected carbon sources for obtaining near-infrared fluorescence and stimuli-responsive behavior in carbon dots that also provide strong fluorescence contrast.